DiaMedica Therapeutics Inc.

NASDAQ:DMAC

Biotechnology

Healthcare
$8.59 -0.17%

-$0.01 today

Market cap
$463.49M
Beta
1.00
P/E (TTM)
-8.8
EPS (TTM)
-$0.65
52W Low $3.48High $10.42

Volume 0.21M

Average 0.19M

DMAC Income Before Tax

Profit after all operating and non-operating items but before income tax.

DiaMedica Therapeutics Inc.NASDAQ: DMAC

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$10.04M, compared with -$7.7M a year earlier. Trailing-twelve-month income before tax was -$35.07M.

Context

  • Income before tax grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$10.04M or moves back toward the trailing-twelve-month quarterly average of -$8.77M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$10.04M-14.9% QoQ
Last fiscal yearDec 2025
-$32.74M-34.1% YoY
LTMMar 2026
-$35.07M-30.0% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.3%——
1 year-34.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(32.74M) USD
Year-over-year change
-34.1%

Income Before Tax vs competitors

How DMAC compares with its peers on the latest reported figures

  • DMAC's LTM Mar 2026 income before tax of -$35.07M is the 2nd highest of the 7 companies compared; the peer median is -$106.24M.
  • Its year-over-year change of -30.0% is the 5th highest of 7, against a peer median of -16.7%.
DMAC Competitors Peer median
Income Before Tax for DMAC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AKBAAkebia Therapeutics, Inc.LTM Mar 2026-$18.76M +58.6%—8.1%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026-$35.07M -30.0%——
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026-$39.95M -162.9%——
BIOABioAge Labs, Inc.LTM Mar 2026-$89.93M -26.6%—871.8%
MAZEMaze Therapeutics, Inc.LTM Mar 2026-$122.54M -330.7%—612.7%
PROKProKidney Corp.LTM Mar 2026-$156.46M +5.8%—17599.3%
DNLIDenali Therapeutics Inc.LTM Jun 2026-$511.35M -6.8%—14188.4%
Peer median (excluding DMAC) -$106.24M-16.7%—871.8%

Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development8.77M7.84M13.11M19.06M24.61M
Selling, General & Admin4.88M6.16M8.16M7.62M9.78M
Operating Expenses13.65M14M21.27M26.68M34.4M
Depreciation & Amortization24K25K30K39K43K
EBITDA(13.54M)(13.62M)(19.31M)(24.38M)(32.7M)
EBITDA Margin—————
Operating Income(13.65M)(14M)(21.27M)(26.68M)(34.4M)
Operating Margin—————
Interest Income0002.3M0
Interest Expense00000
Other Income / Expenses82K353K1.93M2.27M1.66M
Income Before Tax(13.56M)(13.65M)(19.34M)(24.41M)(32.74M)
Pre-Tax Margin—————
Income Tax Expense28K28K43K30K28K
Net Income(13.59M)(13.68M)(19.38M)(24.44M)(32.77M)
Net Margin—————
EPS (Basic)(0.65)(0.52)(0.60)(0.60)(0.70)
EPS (Diluted)(0.65)(0.52)(0.60)(0.60)(0.70)
Weighted Avg Shares20.77M26.44M32.57M40.4M46.98M
Weighted Avg Shares (Diluted)20.77M26.44M32.57M40.4M46.98M

DiaMedica Therapeutics Inc.

NASDAQ:DMAC

Intrinsic Alpha fair value

Locked

Current Price

$8.59

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.